Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saad Z Usmani

Showing results (11-20 of 253) with videos related to

Pageof 26
Sort By:
Current Molecular Medicine|July 16, 2009
17 AAG for HSP90 inhibition in cancer--from bench to bedsideSaad Z Usmani, Robert Bona, Zihai Li
Hematology/Oncology Clinics of North America|June 17, 2023
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific AntibodiesKarthik Nath, Sham Mailankody, Saad Z Usmani
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Multiple myeloma: is it time for biomarker-driven therapy?Manisha Bhutani, Ola Landgren, Saad Z Usmani
Blood Reviews|August 18, 2023
Aiming for the cure in myeloma: Putting our best foot forwardNoffar Bar, Ross S Firestone, Saad Z Usmani
Journal for Immunotherapy of Cancer|November 7, 2025
Mileage matters: long-distance performance of CARs in multiple myelomaEric M Jurgens, Saad Z Usmani, Maximilian Merz
Asian Pacific Journal of Cancer Prevention : APJCP|March 3, 2010
Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib eraSaad Z Usmani, Shakeeb A Yunus, Yasser Jamal
Clinical Lymphoma, Myeloma & Leukemia|October 13, 2020
Chimeric Antigen Receptor T-cell Therapy for Multiple MyelomaShebli Atrash, Syed Abbas Ali, Saad Z Usmani
Blood Cancer Discovery|October 12, 2023
An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple MyelomaRoss Firestone, Alexander M Lesokhin, Saad Z Usmani
Blood Cancer Journal|April 30, 2021
Chromosome 1q21 abnormalities in multiple myelomaTimothy M Schmidt, Rafael Fonseca, Saad Z Usmani
Immunotargets and Therapy|July 8, 2021
CD38-Directed Therapies for Management of Multiple MyelomaHamza Hashmi, Muhammad Husnain, Ali Khan, et al.
Pageof 26

Showing results (11-20 of 253) with videos related to

Sort By:
Pageof 26
Current Molecular Medicine|July 16, 2009
17 AAG for HSP90 inhibition in cancer--from bench to bedsideSaad Z Usmani, Robert Bona, Zihai Li
Hematology/Oncology Clinics of North America|June 17, 2023
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific AntibodiesKarthik Nath, Sham Mailankody, Saad Z Usmani
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Multiple myeloma: is it time for biomarker-driven therapy?Manisha Bhutani, Ola Landgren, Saad Z Usmani
Blood Reviews|August 18, 2023
Aiming for the cure in myeloma: Putting our best foot forwardNoffar Bar, Ross S Firestone, Saad Z Usmani
Journal for Immunotherapy of Cancer|November 7, 2025
Mileage matters: long-distance performance of CARs in multiple myelomaEric M Jurgens, Saad Z Usmani, Maximilian Merz
Asian Pacific Journal of Cancer Prevention : APJCP|March 3, 2010
Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib eraSaad Z Usmani, Shakeeb A Yunus, Yasser Jamal
Clinical Lymphoma, Myeloma & Leukemia|October 13, 2020
Chimeric Antigen Receptor T-cell Therapy for Multiple MyelomaShebli Atrash, Syed Abbas Ali, Saad Z Usmani
Blood Cancer Discovery|October 12, 2023
An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple MyelomaRoss Firestone, Alexander M Lesokhin, Saad Z Usmani
Blood Cancer Journal|April 30, 2021
Chromosome 1q21 abnormalities in multiple myelomaTimothy M Schmidt, Rafael Fonseca, Saad Z Usmani
Immunotargets and Therapy|July 8, 2021
CD38-Directed Therapies for Management of Multiple MyelomaHamza Hashmi, Muhammad Husnain, Ali Khan, et al.
Pageof 26